Overview

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

Status:
Terminated
Trial end date:
2010-08-19
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins